Taiba Makes Strategic Investment in Immuneel Therapeutics to Advance CAR T-cell Research
Details : The intended to advance CAR T-cell research development of Phase 2 trial for CD19 CAR-T IMN-003A (varnimcabtagene autoleucel) targeting B-cell malignancies, including leukemia and lymphoma.
Product Name : IMN-003A
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
July 30, 2024
Immuneel's CAR-T Cell Therapy Reports Positive In Early Phase-2 Trials In India
Details : IMN-003A (varnimcabtagene autoleucel) has demonstrated early, deep and durable remission in children and adults with relapsed / refractory B cell malignancies.
Product Name : IMN-003A
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 20, 2022
Lead Product(s) : Xentuzumab,Everolimus,Exemestane
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Agreement
Aragen Announces Expansion of Research Agreement with Boehringer Ingelheim
Details : Xentuzumab* (BI 836845) is a humanized immunoglobulin G (IgG) 1 monoclonal antibody (mAb) that targets insulin-like growth factor (IGF) ligands IGF-1 and IGF-2 for treatment of breast cancer.
Product Name : BI 836845
Product Type : Antibody
Upfront Cash : Undisclosed
June 29, 2021
Lead Product(s) : Xentuzumab,Everolimus,Exemestane
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Everolimus
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biocon Expands its Generic Formulations Portfolio with the Launch of Everolimus Tablets in the US
Details : Everolimus tablets, a generic version of Afinitor® have been introduced in four strengths of 2.5mg, 5mg, 7.5mg and 10mg, with the 10 mg tablet used to treat certain types of cancers and tumours.
Product Name : Afinitor-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2021
Lead Product(s) : Everolimus
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable